Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business leadership change

CordenPharma CEO Transition Herbeaux Quirmbach

Analysis based on 6 articles · First reported Sep 15, 2026 · Last updated Sep 17, 2026

Sentiment
5
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The CEO transition at a private, Astorg-backed CDMO is a routine leadership change with limited direct read-through for public markets, though it signals continuity of CordenPharma's growth and capacity-expansion strategy in the pharmaceutical services sector. Investors in listed CDMO peers and Astorg portfolio watchers may note the appointment of an experienced operator from Hovione as a neutral-to-mildly-positive signal for the company's execution and customer delivery.

pharmaceutical services contract manufacturing private equity

CordenPharma, a global pharmaceutical contract development and manufacturing organization (CDMO) backed by private equity firm Astorg, announced the appointment of Dr. Jean-Luc Herbeaux as Chief Executive Officer effective 1 October 2026. Herbeaux succeeds Dr. Michael Quirmbach, who served as CEO since 2019 and spent 12 years with the company, during which CordenPharma grew annual revenue from 245 million euros to more than 1 billion euros. Quirmbach will remain actively involved as a Board Member and Senior Advisor. Herbeaux joins from Hovione, an international CDMO where he was CEO for more than four years and previously COO, and earlier held senior roles at specialty chemicals group Evonik. The transition follows a period of significant expansion, including the acquisition of peptide CDMO AmbioPharm and continued investment in manufacturing capacity. CordenPharma now employs approximately 3,500 people across 13 facilities in Europe, North America and Asia, and reported sales of 960 million euros in the 2025 financial year. Astorg, which acquired CordenPharma in 2022, expressed support for the new leadership, with Co-Managing Partner Judith Charpentier praising Quirmbach's contribution and welcoming Herbeaux's operational and CDMO experience. Herbeaux stated his focus will be disciplined execution of growth plans, deepening customer partnerships and strengthening capabilities.

70 Michael Quirmbach transitioned to board CordenPharma
40 CordenPharma acquired AmbioPharm
20 Astorg acquired CordenPharma
priv
CordenPharma is the central entity undergoing a planned CEO transition from Michael Quirmbach to Jean-Luc Herbeaux effective 1 October 2026. The change is framed as continuity of its growth strategy, with Quirmbach remaining as Board Member and Senior Advisor.
Importance 95.0 Sentiment 10.0
per
Herbeaux is appointed incoming CEO of CordenPharma, bringing CEO and COO experience from Hovione and prior senior roles at Evonik. His appointment is presented as strengthening operational execution and customer delivery.
Importance 90.0 Sentiment 15.0
per
Quirmbach steps down as CEO after leading CordenPharma since 2019 and through 12 years of growth from 245 million euros to over 1 billion euros in revenue. He remains on the board and as Senior Advisor, preserving continuity.
Importance 85.0 Sentiment 5.0
priv
Astorg, the pan-European private equity owner of CordenPharma since 2022, supports and drives the leadership transition. Its continued backing is central to CordenPharma's next growth phase.
Importance 70.0 Sentiment 5.0
priv
Hovione is the international CDMO from which Herbeaux departs after more than four years as CEO and prior COO role. The loss of its chief executive is a notable but unquantified management change for the firm.
Importance 40.0 Sentiment 0.0
per
Charpentier, Co-Managing Partner and Co-Head of Flagship at Astorg, commented on the transition, crediting Quirmbach's contribution and expressing confidence in Herbeaux. She represents the owner's endorsement of the new leadership.
Importance 30.0 Sentiment 0.0
priv
AmbioPharm is referenced as the peptide CDMO recently acquired by CordenPharma, cited as evidence of the company's expansion under the outgoing CEO. It plays no active role in the leadership change itself.
Importance 20.0 Sentiment 0.0
stock
Evonik is mentioned only as a former employer where Herbeaux held senior roles before joining Hovione. It has no direct operational role in the transition.
Importance 15.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.